• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

Is chronic OM a disease of microbial biofilm?


Investigators' analysis of biopsy specimens from the middle-ear mucosa of children with otitis media with effusion (OME) and recurrent OM upheld the so-called biofilm hypothesis: Namely, chronic OM is associated with the presence of biofilm (aggregated bacteria that usually adhere to a surface-in these cases, the middle-ear mucosa). The study was conducted in 26 children who were undergoing placement of a tympanostomy tube for treatment of OME and OM; controls were three children and five adults undergoing cochlear implantation.

Confocal laser scanning microscopic (CLSM) images were obtained from biopsy specimens of the middle-ear mucosa and were evaluated for biofilm morphology using generic stains and species-specific probes for Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis. Effusions, when present, were evaluated by polymerase chain reaction and culture for evidence of pathogen-specific nucleic acid sequences and bacterial growth.

Of the 26 children (mean age, 2.5 years) undergoing placement of a tympanostomy tube, 13 (50%) had OME, 20 (77%) had recurrent OM, and seven (27%) had both diagnoses. CLSM revealed biofilm on 46 (92%) of 50 middle-ear mucosa specimens from these children, including those that were not associated with effusion. Biofilm was not observed on any of the eight control middle-ear mucosa specimens (Hall-Stoodley L et al: JAMA 2006;296:202).

Related Videos
Lawrence Eichenfield, MD
Lawrence Eichenfield, MD | Image credit: KOL provided
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Related Content
© 2024 MJH Life Sciences

All rights reserved.